Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?

Sarma, 2005, A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997, J Urol, 173, 2048, 10.1097/01.ju.0000158443.13918.d6 Wei, 2005, Urologic diseases in America project: benign prostatic hyperplasia, J Urol, 173, 1256, 10.1097/01.ju.0000155709.37840.fe Black, 2006, An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia, Am J Manag Care, 12, S99 Chapple, 2001, Lower urinary tract symptoms suggestive of benign prostatic obstruction—TRIUMPH: design and implementation, Eur Urol, 39, 31, 10.1159/000052565 van Exel, 2006, Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study, Eur Urol, 49, 92, 10.1016/j.eururo.2005.09.016 Hutchison, 2006, Characteristics of patients presenting with LUTS/BPH in six European countries, Eur Urol, 50, 555, 10.1016/j.eururo.2006.05.001 Debruyne, 2006, Medical management of BPH: the debate continues, Eur Urol, 50, 416, 10.1016/j.eururo.2006.06.045 de la Rosette JJ, Alivizatos G, Madersbacher S, et al. European Association of Urology: guidelines on benign prostatic hyperplasia. Update March 2004. Available at www.uroweb.nl. Accessed 22 January 2007. Hutchison, 2007, The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries, Eur Urol, 51, 207, 10.1016/j.eururo.2006.06.012 Montorsi, 2006, Safety and tolerability of treatment for BPH, Eur Urol Suppl, 5, 1004, 10.1016/j.eursup.2006.08.012 Emberton, 2003, Benign prostatic hyperplasia: a progressive disease of aging men, Urology, 61, 267, 10.1016/S0090-4295(02)02371-3 Rhodes, 1999, Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old, J Urol, 161, 1174, 10.1016/S0022-5347(01)61621-5 Jacobsen, 1996, Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men, J Urol, 155, 595, 10.1016/S0022-5347(01)66461-9 Roberts, 2000, Longitudinal changes in peak urinary flow rates in a community based cohort, J Urol, 163, 107, 10.1016/S0022-5347(05)67984-0 McConnell, 2003, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med, 349, 2387, 10.1056/NEJMoa030656 Crawford, 2006, Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo, J Urol, 175, 1422, 10.1016/S0022-5347(05)00708-1 Roehrborn, 2006, Definition of at-risk patients: baseline variables, BJU Int, 97, 7, 10.1111/j.1464-410X.2006.06098.x 2003, AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations, J Urol, 170, 530, 10.1097/01.ju.0000078083.38675.79 Flanigan, 1998, 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study, J Urol, 160, 12, 10.1016/S0022-5347(01)63011-8 Djavan, 2004, Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years, Urology, 64, 1144, 10.1016/j.urology.2004.08.049 Djavan, 2005, Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting, World J Urol, 23, 253, 10.1007/s00345-005-0005-7 Slawin, 2004, The use of nomograms for selecting BPH candidates for dutasteride therapy, Rev Urol, 6, S40 Roehrborn, 1999, Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia, Urology, 53, 581, 10.1016/S0090-4295(98)00655-4 Roehrborn, 2000, Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study, J Urol, 163, 13, 10.1016/S0022-5347(05)67962-1 Fong, 2005, Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia, Curr Opin Urol, 15, 35, 10.1097/00042307-200501000-00009 Imperato-McGinley, 2002, Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency, Mol Cell Endocrinol, 198, 51, 10.1016/S0303-7207(02)00368-4 Iehle, 1999, Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue, J Steroid Biochem Mol Biol, 68, 189, 10.1016/S0960-0760(99)00030-8 Frye, 2006, Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor, Curr Top Med Chem, 6, 405, 10.2174/156802606776743101 McConnell, 1998, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia, N Engl J Med, 338, 557, 10.1056/NEJM199802263380901 Roehrborn, 2002, Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia, Urology, 60, 434, 10.1016/S0090-4295(02)01905-2 Roehrborn, 2006, The motion: prevention of prostate cancer with a 5α-reductase inhibitor is feasible, Eur Urol, 49, 396, 10.1016/j.eururo.2005.12.075 Novara, 2006, Critical review of guidelines for BPH diagnosis and treatment strategy, Eur Urol Suppl, 5, 418, 10.1016/j.eursup.2006.02.005